Cite
MLA Citation
Reinhard Dummer et al.. “Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.” Lancet oncology, vol. 19, no. 10, 2018, pp. 1315–1327. http://access.bl.uk/ark:/81055/vdc_100070083379.0x000018